Boston, MA 04\/17\/2014 (wallstreetpr) –\u00a0A multi-specialty healthcare Company, Allergan, Inc. <\/b>(NYSE:AGN)<\/b> has earned global recognition for developing specialty pharmaceuticals.<\/p>\n
New alliances<\/b><\/p>\n
The acquisition of SkinMedica, Inc. and the entire share capital of MAP Pharmaceuticals Inc. has come has a robust booster to the business of the company. Recently, the company sold off its obesity intervention business to Apollo Endosurgery.<\/p>\n
Future commitments<\/b><\/p>\n
Research is on to make some path breaking interventions for the treatment of diseases like migraine, depression, retinal diseases and glaucoma among others. Once these drugs are in the market, they are sure to bring relief to a large number of patients worldwide.<\/p>\n
Other professional services<\/b><\/p>\n
Apart from being a drug maker, AGN also offers other services to the fraternity in the form of medical information, Regional Scientific Services, Medical Education Grants, Investor initiated Trial Support and Publication Assistance. This service oriented approach is something that has put Allergan, Inc. (NYSE:AGN) in a different league altogether.<\/p>\n
Ethical practices<\/b><\/p>\n
Wherever possible, the company is committed to decreasing or doing away with animal testing of its products during the research and development phase. The company practices the highest level of ethics, transparency and compliance at all levels of business starting from backward integration up to forward integration.<\/p>\n
Allergan, Inc. (NYSE:AGN) has a global footprint in over 100 countries of the world and with a man force of nearly 11,400 employees; it seeks to be a force to reckon with. The company has come a long way from being an eye care specialist to a multi specialty health care company, and it is this ability to diversify that has put the company on to a stupendous growth trajectory.<\/p>\n
Like every other company in the pharma industry, AGN also invests heavily in research and development. It has world class research and development facility which helps it to come up with product innovation best suited for its ultimate stakeholder; the patients. It is this thirst for innovation that gets Allergan, Inc. (NYSE:AGN) support from all quarters of its patients, health care professionals, staff and shareholders.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 04\/17\/2014 (wallstreetpr) –\u00a0A multi-specialty healthcare Company, Allergan, Inc. (NYSE:AGN) has earned global recognition for developing specialty pharmaceuticals. New alliances The acquisition of SkinMedica, […]<\/p>\n","protected":false},"author":6,"featured_media":19760,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[6035,6036],"stock_ticker":[],"class_list":["post-19759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-allergan-inc-nyseagn","tag-nyseagn","entry"],"acf":[],"yoast_head":"\n